Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 676 press releases before 2019
-
US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes
-
US FDA approves orphan drug MYALEPT™ (metreleptin for injection)
-
AstraZeneca scientists to work alongside researchers at Cancer Research UK Cambridge Institute
-
AstraZeneca PLC fourth quarter and full year results 2013
-
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance
-
AstraZeneca and Shanghai Institutes of Biological Sciences announce research collaboration
-
XIGDUO™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes
-
AstraZeneca provides update at JP Morgan Healthcare Conference on progress to achieve scientific leadership and return to growth
-
US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes
-
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
